A New Treatment Option for Uncommon EGFR Mutations (BMIC-023)

A New Treatment Option for Uncommon EGFR Mutations (BMIC-023)

User Photo
BeaconMedIC

2 years
730 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dr. Jack West reviews the new FDA approval for afatinib (Gilotrif) for specific uncommon EGFR mutations, including G719X, L861Q, and S768I, in advanced NSCLC.
Up Next Autoplay
>